{ "@context": "https://frontierpicks.com/schemas/dossier.v1.json", "ticker": "UFPT", "name": "UFP Technologies, Inc.", "url": "https://frontierpicks.com/dossiers/UFPT/", "json_url": "https://frontierpicks.com/dossiers/UFPT.json", "status": "DORMANT", "current_conviction": "LOW", "graded_conviction": null, "archetype": { "code": "a2", "n": 2 }, "current_thesis": "UFP Technologies' medical-outsourcing recovery case requires a weekly reclaim of $300 before a weekly close below $273. The prior case failed at the 2026-09-18 close, while CI Medical's acquisition release provides no financial contribution to establish renewed earnings acceleration.", "invalidation_trigger": "A weekly close below $273 ends the provisional recovery case by breaching the intraday lows recorded on 2026-09-15 and 2026-09-18; the earlier $288.79 weekly threshold has already been breached.", "catalyst_date": null, "outcome": "OPEN", "outcome_date": null, "invalidation_fired": null, "themes": [ "medtech-diagnostics" ], "tags": [], "sources": [], "notes": [ "UFP Technologies issues no forward revenue or EPS guidance; the quarterly print is the only scheduled company update.", "The 2026-08-24 investor deck states 3-5 year targets, not annual guidance — it commits the company to no 2026 or 2027 number.", "MedTech is the largest end-market and top-five customer growth is disclosed as a separate line, so programme concentration is a standing exposure.", "Manufacturing includes Dominican Republic operations, leaving US trade and tariff policy on imported medical components a recurring input to gross margin.", "Sell-side coverage is thin: TipRanks showed insufficient data for a consensus target as of 2026-08-29, so aggregator averages can move on a single revision.", "Leadership as of the 2026-08-04 Q2 call: Mitchell Rock is CEO, R. Jeffrey Bailly is Executive Chairman." ], "body_markdown": "## Current Thesis\n\nUFP Technologies' medical-outsourcing recovery case requires a weekly reclaim of the former $300 shelf before a weekly close below $273 ends it. This is a new, low-conviction recovery hypothesis: the previously published $288.79 weekly invalidation threshold was breached by the 2026-09-18 adjusted close of $276.69. The earlier case has failed; the lower threshold does not preserve it.\n\nThe post-Q2 narrative is dead — that is the structural inference from the 2026-09-18 close below both the September 4 reference close and the former $300 shelf. The operating record remains stronger than the price structure: the August 3 release reported Q2 organic growth of 12.4%. [Q2 earnings release](https://www.sec.gov/Archives/edgar/data/914156/000162828026051846/ufpt-20260803x8kxexx991.htm)\n\nA company release dated 2026-09-09 disclosed the acquisition of CI Medical, a medical-device precision-printing business. It supplied no purchase price, acquired revenue or earnings contribution, so the acquisition cannot yet support a quantified earnings upgrade. [CI Medical release](https://ufpt.com/news/ufp-technologies-expands-medical-capabilities-with-acquisition-of-ci-medical/)\n\n## Bull Case\n\n- **Organic growth accelerated in Q2.** The 2026-08-03 release reported Q2 sales of $174.0 million, up 15.1%, and organic growth of 12.4%, compared with first-half organic growth of 6.8%. These are reported results, not a forecast of persistence. [Q2 earnings release](https://www.sec.gov/Archives/edgar/data/914156/000162828026051846/ufpt-20260803x8kxexx991.htm)\n- **Growth extended beyond major customers.** In the same August 3 release, management reported Q2 growth of 14.7% among the top five customers and 19.7% across the remaining medical-technology business. That supports breadth within the reported quarter; it does not establish a durable trend. [Q2 earnings release](https://www.sec.gov/Archives/edgar/data/914156/000162828026051846/ufpt-20260803x8kxexx991.htm)\n- **Acquisition adds a manufacturing capability.** The release dated 2026-09-09 identifies CI Medical's expertise in printing on difficult medical-device substrates. The capability is documented; the financial benefit remains undisclosed. [Company announcement](https://ufpt.com/news/ufp-technologies-expands-medical-capabilities-with-acquisition-of-ci-medical/)\n\n## Bear Case\n\n- **The prior threshold has failed.** The 2026-09-18 adjusted close of $276.69 was below the published $288.79 weekly threshold. The supplied adjusted series places the shares 17.4% below their $334.84 52-week high as of September 18.\n- **Capacity benefits are taking longer.** In the 2026-08-03 release, management said Dominican Republic investment benefits were taking longer than anticipated and described near-term mix and margin pressure in US operations. This qualifies the expansion story despite Q2 gross margin of 29.3%. [Management commentary](https://www.sec.gov/Archives/edgar/data/914156/000162828026051846/ufpt-20260803x8kxexx991.htm)\n- **A recent valuation revision declined.** Argus's quantitative report dated 2026-09-09 lowered its UFPT price target to $317. That is a third-party valuation revision, not evidence of improving company orders. [Argus report listing](https://finance.yahoo.com/research/reports/ARGUS_6332_QuantitativeReport_1788912000000)\n\n## Setup & Price Structure\n\nThe September 18 adjusted price snapshot shows a three-month gain of 18.6% and a 14-period relative strength index (RSI) of 20.4. Positive trailing performance and weak recent momentum coexist; neither establishes a reversal. A current moving-average value is missing, so distance from a rising average cannot be stated.\n\nPublic daily history records intraday lows of $273.00 on 2026-09-15 and 2026-09-18. Those observations provide a dated reference for the recovery hypothesis, but the sample is too small to establish a durable base. A weekly close above the former $300 shelf defines the recovery outcome; a weekly close below $273 invalidates it first. [Daily price history](https://stockanalysis.com/stocks/ufpt/history/)\n\nPositioning evidence remains limited. The Form 4 filed 2026-08-27 disclosed director Marc Kozin's August 25 sales at $303.58–$305.41. This establishes insider supply on that date, not the cause of September weakness. The August 4 Benzinga movers coverage documents attention around earnings, but that isolated coverage does not establish retail crowding.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-09-30 — Q3 period ends.** This is an accounting milestone, not a results announcement. No company-confirmed earnings release or investor event within the next 30 days was identified on the company's calendar as of 2026-09-20. [Company news and events](https://ufpt.com/news/)\n- **~2026-11-02, est. Q3 results.** MarketBeat identifies this as an estimated date and explicitly says the company has not confirmed it. This later event matters because it can test organic-growth persistence and disclose acquisition economics; acquired revenue alone would not confirm organic acceleration. [Earnings calendar](https://www.marketbeat.com/stocks/NASDAQ/UFPT/earnings/)\n\n## What Would Change Our Mind\n\nFailure of the September reference lows would end the provisional recovery case: a weekly close below $273 would breach the intraday lows recorded on September 15 and September 18. The former $288.79 invalidation has already occurred and remains a failed forecast on the record. [Price history](https://stockanalysis.com/stocks/ufpt/history/)\n\nA weekly close above $300 before that breach would establish the defined price recovery. Fundamental confidence would require a separate operating test: Q3 organic growth below the first-half 2026 rate of 6.8% would contradict the acceleration argument. Management's 2026-08-24 presentation described growth and margin targets over three to five years, so those targets cannot substitute for the next quarterly result.\n\n## Correlation Notes\n\nThis remains a single-name recovery case. The August 3 release reported growth across medical customers while non-medical business was flat, supporting a medical-demand exposure rather than a broad industrial explanation. [Q2 release](https://www.sec.gov/Archives/edgar/data/914156/000162828026051846/ufpt-20260803x8kxexx991.htm) No paired sector-return series accompanies the September 18 observations, so a measured sector correlation or group-led recovery claim is unsupported.", "first_seen": "2026-08-13", "last_analyzed": "2026-09-20T13:05:25+00:00", "last_synthesized": "2026-09-20", "last_update_source": "watchlist_research", "license": "Content © FrontierPicks. Cite the canonical URL." }